Long-term unsupervised mobility assessment in movement disorders by Warmerdam, Elke et al.
 
page 1 of 18 
Long-term unsupervised mobility assessment in movement disorders  
Elke Warmerdam, Jeffrey M. Hausdorff, Arash Atrsaei, Yuhan Zhou, Anat Mirelman, Kamiar Aminian, 
Alberto J. Espay, Clint Hansen, Luc J.W. Evers, Andreas Keller, Claudine Lamoth, Andrea Pilotto, Lynn 
Rochester, Gerhard Schmidt, Bastiaan R. Bloem, Walter Maetzler 
Department of Neurology, Kiel University, Kiel, Germany (E Warmerdam MSc, C Hansen PhD, Prof W Maetzler 
MD) 
Faculty of Engineering, Kiel University, Kiel, Germany (E Warmerdam MSc, Prof G Schmidt PhD) 
Center for the Study of Movement, Cognition, and Mobility, Tel Aviv Sourasky Medical Center; Department 
of Physical Therapy, Sackler Faculty of Medicine and Sagol School of Neuroscience, Tel Aviv University, Israel 
(Prof J M Hausdorff PhD, Prof A Mirelman PhD) 
Rush Alzheimer’s Disease Center and Department of Orthopaedic Surgery, Rush University Medical Center, 
Chicago, Illinois, USA (Prof J M Hausdorff PhD) 
Laboratory of Movement Analysis and Measurement, École Polytechnique Fédérale de Lausanne, Lausanne, 
Switzerland (A Atrsaei MSc, Prof K Aminian PhD) 
University of Groningen, University Medical Center Groningen, Center for Human Movement Sciences, 
Groningen, The Netherlands (Y Zhou MSc, C Lamoth PhD) 
Radboud University Medical Center; Donders Institute for Brain, Cognition and Behaviour; Department of 
Neurology; Nijmegen, The Netherlands (LJW Evers BSc, Prof B R Bloem PhD) 
Gardner Family Center for Parkinson's Disease and Movement Disorders, University of Cincinnati, Cincinnati, 
Ohio, USA (Prof A J Espay MD) 
Center for Bioinformatics, Chair for Clinical Bioinformatics, Saarland University, Saarbrücken, Germany (Prof 
A Keller PhD) 
Stanford University School of Medicine Office, Department of Neurology and Neurological Sciences (Prof A 
Keller PhD)  
Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy (A Pilotto MD) 
Parkinson’s Disease Rehabilitation Centre, FERB ONLUS – S. Isidoro Hospital, Trescore Balneario (BG), Italy (A 
Pilotto MD) 
Institute of Neuroscience, Newcastle University, Newcastle Upon Tyne, UK (Prof L Rochester PhD) 
Newcastle upon Tyne Hospitals National Health Service Foundation Trust, Newcastle upon Tyne, UK (Prof L 
Rochester PhD)  
 
Corresponding author: Prof. Jeffrey M. Hausdorff, Center for the Study of Movement, Cognition, and 
Mobility, Neurological Institute, Tel Aviv Sourasky Medical Center, 6 Weizmann Street, Tel Aviv, Israel, Tel: +972 
3 697 3081, Fax: +972 3 697 4911, E-mail: jhausdor@tlvmc.gov.il 
 
 
page 2 of 18 
  
Glossary of unusual terms and terms used in the biomechanical field 
 
Cadence The rate at which a person steps (about 110-115 steps/min in 
healthy adults). 
Chair rise peak power The maximum power that is exerted to lift the body’s centre of 
mass during a sit to stand movement.1 
Daily-living This term, also referred to as free-living, real-world, or community-
living, is used to distinguish testing within the normal environment 
of a participant from testing in a standardized setting, such as in 
the clinic or laboratory setting.  
Hawthorne effect The change in behaviour of participants because of the awareness 
of being studied.2 
Inertial measurement units Sensors that measure acceleration and/or angular velocity. They 
can measure the quality and quantity of movement using 
specifically developed algorithms. 
Median walking acceleration The median of the magnitude of the acceleration during walking. 
Mobile health technologies Umbrella term for wearable or portable / domestic-integrated 
devices that can provide objective measures and that include 
digital applications, as well as body-worn (adhered to a body 
surface, mainly inertial measurement units) or frequently used 
patient-centred devices (e.g., smartphone, keyboard). Here we 
focus on technologies that can measure the frequency and quality 
of movement and mobility characteristics.3 
Postural transitions Sit to stand and stand to sit movements, or turning over in bed. 
Reverse white coat effect A change (typically an improvement) in a clinical parameter 
because it is measured in a clinical setting (it can be seen as the 
opposite of the white coat syndrome in hypertension). 
Stance time The time one leg is in contact with the surface during a step that is 
taken during walking. 
Step time The time it takes to perform one step (i.e., the time between initial 
contact of one foot and the initial contact of the contralateral 
foot). 
Stride time Also known as gait cycle time. This is the time to perform two steps 
(i.e., the time between initial contact of one foot and the next 
initial contact of the same foot). 
Swing time The time one leg is not in contact with the surface during a stride 
that is taken during walking. In healthy young adults, swing time is 
about 40% of the stride time. With aging and disease, the time 
spent in swing time often gets smaller. 
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Supervised assessment This refers to the traditional, conventional mode of assessing 
mobility in a lab or clinical setting. Typically, this is a qualitative or 
semi-quantitative “one-time snapshot” evaluation of mobility that 
is conducted by a trained healthcare professional. 
Unsupervised assessment This refers to the quantitative assessment of mobility in the home 
and daily-living environment that is conducted continuously with 
new, mainly mobile, health technologies over relatively long 
periods of time. 
Wearables Mobile devices worn on the body, e.g. inertial measurement units, 
smartwatches or Holter electrocardiogram monitors. 
White coat effect A change (typically worsening)  in a parameter because it is 
measured in a clinical setting (a well-known example is the white 
coat effect that leads to an increase in blood pressure). 
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Abstract 
Digital health technologies that quantify mobility in unsupervised, daily-living environments are 
emerging as a complementary evaluation approach in neurology. Data collected in these ecologically 
valid, patient-relevant settings can overcome significant limitations of conventional clinical 
assessments. Unsupervised assessments can capture fluctuating and rare events and have the 
promise of supporting clinical decision-making and serving as outcomes in clinical trials. However, 
studies that directly compared assessments made in unsupervised and supervised (i.e. in the lab or 
clinical) settings point to large disparities, even in the same parameters of mobility (up to 180% 
difference). These differences appear to be influenced by psychological, physiological, cognitive, 
environmental, and technical factors and by the specific aspect of mobility and diagnosis. To facilitate 
the successful adaptation of the unsupervised assessment of mobility in the clinic and in clinical 
trials, clinicians and future work should take into account these disparities and the multiple factors 
that contribute to them. 
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Introduction 
Deficits in mobility are common among neurological patients and often impact daily-living activities, 
work, and socialization.4 These deficits predict morbidity, cognitive decline and mortality5–8 and 
negatively affect quality of life, especially in patients with neurological movement disorders.9,10 For 
example, in patients with PD, health-related quality of life is strongly associated with the activities 
and participation components of the International Classification of Functioning, Disability and Health 
(ICF model).11 It is, therefore, crucial for healthcare professionals to obtain a full and objective 
evaluation of a patient’s mobility as a basis for individually tailored clinical decision-making and 
prognostication. Currently, mobility assessments are mainly performed under supervised conditions 
in a lab or hospital using standardized, mostly qualitative or semi-structured evaluations.12–14 
However, many patients perform paradoxically well when they know that they are being observed. 
Moreover, various clinically relevant events are difficult to capture during these “snapshot” 
observations, either because they take place over long periods of time (e.g., amount of physical 
activity), are rare (e.g., falls or freezing episodes15), occur at night (e.g., sleep disturbances), or have 
complex fluctuating patterns (e.g., the response to dopaminergic treatment in Parkinson's disease, 
PD). To reliably evaluate such events, it is necessary to measure patients unobtrusively and for much 
longer periods of time, while they move about freely and unsupervised in their daily-living 
environment. 
Recent reviews describe the promise of unsupervised assessments of mobility using novel 
technologies.3,16 Although very different from other daily-living acquired parameters already used in 
clinical routine, such as the Holter electrocardiogram17,18 and blood glucose monitoring19, these 
reviews suggest that the long-term evaluation of mobility will soon become increasingly relevant for 
personalised clinical decision-making in neurology. Unsupervised assessments may save time and 
costs by capturing health-related data largely independent of the availability of healthcare services. 
This is particularly important for patients living in rural areas or developing countries where the 
number of healthcare professionals is small relative to the population size.16 Finally, unsupervised 
assessments offer patients the opportunity to become more actively involved, e.g., by using their 
own devices (such as smartphones) and receiving feedback about their own daily-living 
performance.20 
Unsupervised assessments of mobility can provide additional and, at least partly, complementary 
information, compared to supervised assessments.  Still, differences with respect to the conventional 
evaluation need to be considered. Here we summarize the existing findings on the poor, weak 
association between mobility assessed in the two settings and discuss potential reasons for the 
observed differences. We then present suggestions for clinical care and future research to help bring 
about the appropriate implementation of unsupervised mobility assessment.  
Unsupervised mobility assessment: State-of-the-art 
Unsupervised assessments are usually done with mobile health technologies that can measure 
physical activity,21–23 evaluate mobility or specific movements such as gait,24–26 or detect specific 
symptoms in unsupervised environments.27–29 The potential added value of unsupervised 
assessments in patients with mobility deficits has been demonstrated in several studies. For 
example, both predicting the risk of future falls and discriminating fallers from non-fallers in older 
adults30–33 and stroke survivors34 appears more accurate when using data collected in the 
unsupervised environment. Indeed, the relevance of unsupervised mobility parameters was recently 
acknowledged by the Food and Drug Administration (FDA)35 and the European Medicines Agency 
(EMA).36 Both regulatory agencies now encourage the inclusion of parameters from unsupervised 
mobility assessments as exploratory endpoints in clinical trials.  
To compare the same features of mobility (i.e., gait, turns, postural transitions) in supervised and 
unsupervised assessments, a systematic search (Search strategy and selection criteria box) was 
performed. Twelve studies conducted in three different populations were identified (older adults, 
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PD, multiple sclerosis (MS); Supplementary Table 1). Strikingly, the same mobility parameters 
obtained in identical subjects differed by -40% to 180% (Figure 1). These differences are much larger 
than those seen after many interventions. Thus, small and even moderate treatment effects might be 
buried under the variations introduced merely by the measurement techniques themselves, if the 
differences between supervised and unsupervised assessments are not appropriately considered.  
Why are supervised and unsupervised measurements different? 
Several reasons could explain the substantial differences in mobility parameters when comparing 
supervised and unsupervised assessments (Table 1). First, unsupervised movements are typically self-
initiated, embedded in a rich behavioural context, and goal-directed. In contrast, movements 
performed in a supervised setting are usually triggered by a command and performed in an isolated, 
standardized setting with limited ecological validity.37 For example, self-initiated finger movements 
activate different brain structures compared to externally triggered movements.38,39 Apparently, the 
brain generates supervised movements using networks that differ from those generating 
unsupervised movements. Moreover, with an external focus, attention is directed to the outcome of 
the action, e.g., leaving the room. With an internal focus, attention is directed to controlling the body 
parts when performing a certain movement.40 An external focus of attention results, at least 
sometimes, in more fluent movements.41  
Second, performance can be influenced by several psychological and physiological phenomena that 
may differ across settings. These factors include alertness, motivation, the white-coat-effect, the 
reverse white-coat-effect, the Hawthorne effect, as well as fatigue, pain, and stress. These effects 
may explain why rising from a chair was performed with lower peak power in unsupervised 
assessments, as compared to supervised assessments, even when these movements were performed 
in an identical environment and with the same equipment.26 Similar disparities have been identified 
for several gait parameters.42 Supervised assessments seemingly provide a measure of someone’s 
best, rather than their usual performance; i.e., they capture "capacity" rather than 
"performance".43,44  
Third, the environment is usually standardized in supervised conditions (e.g., walking in a clean and 
sterile environment, without distractions), but much more variable in unsupervised conditions (e.g., 
furniture, lighting, patterns, color of the environment, obstacles). This can induce large variability and 
asymmetry in mobility patterns, as shown by studies that assessed walking through busy corridors 
and through a city centre.45,46 Different types of seats (e.g., firm chair, armchair, low couch) in 
unsupervised conditions can also partially explain the greater variability observed in postural 
transitions in daily-living.26,32,47,48 Moreover, asymmetry can be introduced through a constrained 
environment that requires gait adaptation or turning in the same direction.  
Fourth, multi-tasking situations are common in unsupervised environments, e.g. walking and talking, 
but uncommon in supervised assessments. This may further contribute to the observed differences. 
Even during supervised dual-task walking, the gait quality was usually “better” compared to 
unsupervised walking.49  
Fifth, the presence of a partner/caregiver can also affect mobility in unsupervised conditions. Indeed, 
social interactions are common during every-day walking, e.g., a spouse who acts as a type of 
external cue to improve walking in PD patients or to relieve anxiety in someone with a cautious gait 
disorder.  
Sixth, technical limitations may add to the differences observed. Most currently available algorithms 
were developed and validated in supervised environments. As the amount and variability of activities 
and mobility are much larger in unsupervised environments, algorithms may have difficulties with 
differentiating similar movements (such as picking something up from the floor and sit-to-stand 
movements) that were not evaluated in the supervised assessment.50,51 Of note, only one study 
found in our systematic search used algorithms that were explicitly validated in both standardized 
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and non-standardized settings.52 A further bias may be introduced by the use of different device 
locations (e.g. waist or ankle). The use of different mobile health technologies (e.g., hardware, 
algorithms)47,53 could play a role but we consider this as relatively limited (Supplementary Figure 1). 
The validation of algorithms for unsupervised daily-living assessments brings new challenges as gold-
standard references are lacking.54,55 
Finally, the current statistical approaches for analysing supervised assessments, e.g., conventional 
means and standard deviations, may not be optimal for characterising complex data coming from the 
unsupervised arena. The supervised assessment typically involves one test, a single snapshot, 
whereas the unsupervised evaluation may include thousands of bouts of walking. It remains to be 
seen how to best compare a single value with values obtained from a distribution (or histogram). 
(Figure 2 and Supplementary Table). Indeed, the tails of an individual's distribution may correspond 
better to clinical endpoints such as fall risk, mobility, limitation in activities, frailty and supervised gait 
speed, than do mean and median values.26,37,56 
Does the type of movement and disease matter? 
Some types of mobility, such as postural transitions, show seemingly larger differences than others 
(e.g., walking) when comparing supervised to unsupervised conditions (Figure 1). This difference may 
even depend on specific parameters. In a study of PD patients, the velocity at the beginning of the 
turn was similar in unsupervised and supervised conditions but was lower at the middle, and 
substantially higher at the end of turns in the unsupervised condition.53  
Interestingly, the type and severity of a disease may also influence the differences between 
supervised and unsupervised assessments (Figure 1).25,57 The differences in stand-to-sit duration 
between both settings were smaller in older adults than PD patients.47 Patients with MS showed a 
different pattern. Their gait speed was similar under supervised and unsupervised assessments,58 
while the “opposite” behaviour compared to PD and older adults was seen for stance, step, and 
swing time.52 The reasons for these observations are not yet clear, but differences in physical, 
attentional and cognitive capabilities may contribute.59 These differences between supervised and 
unsupervised performance may even be relevant at a subgroup level. The above-reported changes in 
turning parameters in PD patients53 differed substantially between fallers and non-fallers, with or 
without fear of falling. Remarkably, fallers with fear of falling showed slower turns in the supervised 
assessment but faster turns in the unsupervised assessment, compared to other PD subgroups.53  
How to implement in clinical routine and future research? 
Unsupervised and supervised measurements of mobility often strikingly differ. As we anticipate that 
unsupervised assessments will become a prerequisite for future clinical decision-making and clinical 
trials, here we provide directions to help move this emerging field forward (see Table 2). 
First, we should acknowledge, as neurologists and other healthcare professionals, patients, and 
researchers, the limited understanding of the association between supervised and unsupervised 
mobility when interpreting data obtained from unsupervised environments. The published literature, 
although not yet fully mature, strongly suggests that any extrapolation of unsupervised mobility 
based on our knowledge obtained from supervised mobility may be substantially influenced by the 
type and subtype of disease as well as the disease stage and may affect all or only parts of a patient’s 
mobility.  
Technical limitations should be addressed, e.g., by using the same mobile health technologies with 
the same body location for both supervised and unsupervised measurements. The algorithms used to 
calculate mobility parameters should be validated, to the degree that is possible, in both settings. 
Another requirement to increase the utility of unsupervised measures is a harmonized reporting of 
parameters, for example as a core dataset, across studies. This should include the reporting of 
metadata, i.e., data that accompany and describe the primary data. The duration of the assessments 
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should be harmonized and the type of movement should be reported in detail.60,61 We must also 
think of validation approaches that go beyond clinical observation and lab analysis tools. Moreover, 
algorithms for mobility assessment should be validated separately for each type of neurological 
movement disorder, as they may be associated with distinct movements patterns.25,62 Even healthy 
people move differently in different ages63,64 and with different fitness levels.65 
Special emphasis must be placed on a more sophisticated analysis of unsupervised data. A promising 
approach is to consider and leverage specific episodes of mobility (e.g., turning, sit-to-stand and 
stand-to-sit movements and other movements performed regularly during the day) and novel 
parameters, such as the distribution and extreme values of mobility parameters (Figure 2).26,37,56,66 
These analyses have only been performed for healthy (older) adults and not yet for neurological 
patients. An example could be the evaluation of the effects of an experimental therapy. This might 
be measured best in its optimum state (visible by improvement in the supervised assessment and, 
e.g., the best 10% of an individual's distribution during unsupervised assessment), while the typical 
and worse values may also be informative of changes throughout the day. Phase 3 trials could use 
this information as outcomes.  
Variability measures can serve as a useful example for how important it is for clinicians and principal 
investigators to have a profound understanding of how their treatment and compounds influence 
mobility in daily-life. Some variability measures are highly influenced by the environment and might 
therefore be measured best in a supervised setting, where it better reflects someone’s capacity.67 In 
the home environment, decreased variability with similar mean values might be a positive outcome if 
the goal of an intervention is to reduce motor response fluctuations in patients with PD. In a trial 
investigating generally undertreated patients, a decrease in variability associated with an 
improvement of mean values can indicate more consistent good performance during the day. In 
trials focusing on behavioural symptoms, increased variability might indicate better adaptability, 
more variable and enriched physical activity, and social interactions. The context is critical.  
More generally, we must evaluate whether data obtained from unsupervised environments provide 
relevant progression and treatment response information, rather than acting as markers of routine, 
fixed behaviours or trait markers. Trait markers could still be good measures of progression, but 
appropriate interpretation is key to utility. For example, the actions performed during daily-living are 
very different per individual but show a surprisingly comparable pattern within an individual.68  
Moreover, statistical approaches should take advantage of the high number of repeated, specific 
movements occurring during long-term observation periods in unsupervised environments (Figure 
2).26,53 Here, also deep learning, machine learning, and artificial intelligence approaches could be 
applied. Such algorithms that “learn” from data have shown remarkable success in making accurate 
predictions in complex problems that previously depended on human skills. Existing examples 
include referral for eye diseases69 and detection of PD motor fluctuations.70  
To better understand the clinical relevance of novel outcomes in the unsupervised settings, future 
work should further explore the relationship between these objective digital measures, on the one 
hand, with conventional measures of mobility, as well as with patient-reported outcome measures 
(PROMs) and caregiver reported outcomes, on the other hand. Both PROMs (in this case subjectively) 
and mobile health technologies (in this case objectively) offer remote measurements in the 
unsupervised setting, and both approaches are potentially more ecologically valid and more 
meaningful to patients and their caregivers than data acquired in the traditional clinical setting. 
Among the studies that we identified, only four assessed correlations with PROMs related to 
mobility, with contrasting findings (Supplementary Table).  
We must also keep in mind that mobile health technologies may cause behavioural changes by 
themselves, even when no feedback is provided (e.g., Hawthorne effect) but especially if feedback is 
provided (e.g., to induce compliance). Studies are needed to investigate: (i) if and when the 
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performance of the user in the unsupervised setting becomes more like that in the supervised setting 
and (ii) whether the induced behavioural changes themselves may have therapeutic effects that 
could interfere with the evaluation. For example, subjects who know that they are equipped with 
mobile health technologies may increase their level of physical activitity, particularly when feedback 
about their own performance is provided. 
Eventually, healthcare professionals should interpret their supervised assessments cautiously, as 
these could have limited value when transferred into daily-life. To improve their value, we 
recommend providing natural, everyday life-like situations and instructions when performing 
supervised assessments. Explicit goals should be given, forcing patients to focus on the goal instead 
of on the actual movements that must be performed to reach the goal.60 For example, instructing a 
sitting person to walk allows for a more naturalistic observation of the sit-to-stand performance, 
because the person focuses more on the walking task rather than the necessary transition from sit-
to-stand. Other opportunities to observe uninstructed movements occur when patients move in the 
waiting room or on their way to the clinician’s office.71 It is also essential to gain as much information 
as possible about the living environment of the person investigated. If the person has cluttered 
furniture at home, healthcare professionals might focus more on assessing mobility in small, 
crowded places instead of large open hospital hallways. In addition, the type of furniture, lighting, 
patterns and other environmental factors might be important.72 
Considering mobility differences between the supervised and unsupervised setting can also be 
relevant for the measurement of other symptoms and deficits. For example, deficits in upper 
extremity movement occur in many neurological patients73 and several methods have been proposed 
to continuously assess upper limb bradykinesia in daily-life74. However, a direct comparison of these 
various symptoms in supervised and unsupervised settings remains largely unexplored. One 
exception is a study that assessed habitual keyboard typing behaviour in PD patients.75 In contrast to 
what we have observed for mobility, this study showed that various keystroke metrics as measured 
in the clinic were strongly correlated with those obtained in at-home settings. This suggests that 
some upper extremity performances (in this case, a measure of bradykinesia) are comparable 
between supervised and unsupervised conditions. These considerations again underscore the need 
to assess different aspects of motor functioning on a case-by-case basis.  
 
Conclusions  
There is rapidly increasing evidence that, depending on whether mobility is assessed under 
supervised or unsupervised conditions, the results can differ substantially.26,37,64 Recognition of these 
striking differences and appreciating the importance of measurements obtained in both settings call 
for expanding our knowledge about unsupervised mobility (recall Table 2). With this in mind, 
unsupervised mobility parameters can be implemented to improve clinical care and, as primary or 
secondary endpoints, in intervention trials. 
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FIGURE LEGENDS 
Figure 1. Percentage change from parameters measured in unsupervised conditions relative to 
supervised conditions. Compared to supervised conditions, the bars to the right of zero indicate a 
higher value and to the left of zero indicate a lower value in unsupervised conditions. Number next to 
the bar is the reference number. The solid filled bars reflect parameters related to gait, the diagonal 
stripes reflect parameters related to turns and the dots reflect parameters related to postural 
transitions. See search strategy and selection criteria box for the study selection criteria and see 
glossary for explanation of parameters. Older adults are defined by mean/median age of the 
respective cohorts ≥60ys. Data was obtained from the papers or from the corresponding author. Note 
that we did not include variability and asymmetry parameters in the figure as they are especially 
sensitive to the environment and are likely higher for unsupervised assessments because of the non-
instructed performance and more variable physical nature of the environment.67 * Instructions in the 
supervised setting were as fast as possible. # Supervised assessment was performed on a treadmill 
with fixed speed, the unsupervised parameters used for the comparison were matched to the 
treadmill speed. $ Only the best postural transitions resported were used to calculate the duration. 
Figure 2. Gait speed measures based on evaluation in the lab (A) and based on daily-living 
evaluation (B) in one older adult (78-year-old woman with a history of falls). The supervised testing 
yields a single value (101 cm/sec), as indicated by the red arrow. In contrast, the daily-living, 
unsupervised testing yields hundreds of “tests” of gait speed and a distribution of values. Multiple 
measurements, in contrast to a single, one-time snapshot, may be highly valuable for the 
improvement of assessment protocols. In many of these tests, gait speed is lower than that seen 
during supervised testing. The daily-living values are based on 30-second walking bouts from a one-
week recording, as in Hillel et al., 2019.49  
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